NasdaqGS - Nasdaq Real Time Price USD

DexCom, Inc. (DXCM)

134.30 +0.44 (+0.33%)
At close: April 18 at 4:00 PM EDT
133.50 -0.80 (-0.60%)
After hours: April 18 at 7:52 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Kevin Ronald Sayer Executive Chairman, CEO & President 2.22M -- 1958
Mr. Jereme M. Sylvain Executive VP, CFO & Chief Accounting Officer 841.14k -- 1980
Mr. Jacob Steven Leach Executive VP & COO 994.13k -- 1978
Mr. Girish Naganathan Executive VP & CTO 423.92k -- 1977
Mr. Michael Jon Brown Executive VP & Chief Legal Officer 954.46k -- 1970
Mr. Shelly Ramasamy Selvaraj Senior VP & Chief Information Officer -- -- 1959
Mr. Sean Christensen Director of Corporate Affairs & Head of Investor Relations -- -- --
Mr. Matthew Dolan Executive Vice President of Strategy, Corporate Development & Dexcom Labs -- -- 1981
Ms. Leverne Marsh Executive Vice President of Marketing -- -- --
Ms. Sadie M. Stern Executive VP & Chief Human Resources Officer -- -- 1975

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200 https://www.dexcom.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
9,500

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Corporate Governance

DexCom, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 6; Compensation: 2.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Apr 25, 2024
DexCom, Inc. Earnings Call

Related Tickers

PODD Insulet Corporation
164.73
-0.92%
 
TNDM Tandem Diabetes Care, Inc.
30.93
-2.58%
 
ALGN Align Technology, Inc.
301.34
+0.40%
 
EW Edwards Lifesciences Corporation
86.45
-0.91%
 
BSX Boston Scientific Corporation
67.42
-0.79%
 
SWAV Shockwave Medical, Inc.
327.52
+0.01%
 
MDT Medtronic plc
79.19
+0.14%
 
ABT Abbott Laboratories
105.27
-0.59%
 
SYK Stryker Corporation
327.45
-2.55%
 
SENS Senseonics Holdings, Inc.
0.4160
+3.43%